Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BCEL Atreca (BCEL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Atreca Stock (NASDAQ:BCEL) 30 days 90 days 365 days Advanced Chart Remove Ads Get Atreca alerts:Sign Up Key Stats Today's Range$0.09▼$0.0950-Day Range$0.09▼$0.0952-Week Range$0.05▼$1.20VolumeN/AAverage Volume4.61 million shsMarket Capitalization$3.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAtreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.Read More… Remove Ads Receive BCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter. Email Address BCEL Stock News HeadlinesAtreca Inc Class A (OTC:BCEL) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comBicycle Therapeutics Is Looking Increasingly AttractiveAugust 20, 2024 | seekingalpha.comMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…March 31, 2025 | Porter & Company (Ad)Atreca, Inc. (BCEL) Stock Price, News, Quote & History - Yahoo FinanceApril 23, 2024 | ca.finance.yahoo.comAtreca, Inc. (0C1.MU)April 21, 2024 | nz.finance.yahoo.comAtreca Inc. Cl AFebruary 18, 2024 | wsj.comAtreca Stock (NASDAQ:BCEL), Short Interest ReportFebruary 15, 2024 | benzinga.comAtreca Inc Announces Executive Departures and Consulting AgreementsFebruary 7, 2024 | msn.comSee More Headlines BCEL Stock Analysis - Frequently Asked Questions How were Atreca's earnings last quarter? Atreca, Inc. (NASDAQ:BCEL) posted its earnings results on Tuesday, November, 2nd. The company reported ($0.74) earnings per share for the quarter, meeting the consensus estimate of ($0.74). When did Atreca IPO? Atreca (BCEL) raised $126 million in an initial public offering on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers. What other stocks do shareholders of Atreca own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atreca investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Micron Technology (MU), Alector (ALEC), Advanced Micro Devices (AMD), PayPal (PYPL) and Meta Platforms (META). Company Calendar Last Earnings11/02/2021Today3/31/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCEL CIK1532346 Webwww.atreca.com Phone(650) 595-2595FaxN/AEmployees130Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-157.90% Return on Assets-71.39% Debt Debt-to-Equity RatioN/A Current Ratio1.58 Quick Ratio1.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book0.04Miscellaneous Outstanding Shares39,624,000Free Float35,146,000Market Cap$3.57 million OptionableOptionable Beta1.03 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:BCEL) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atreca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atreca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.